Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nordstjernan issues call options to senior executives at Swedol

Senior executives within the Swedol Group have been offered an opportunity to acquire call options in Swedol AB (publ) on market terms. The call options were issued by Nordstjernan AB, the principal owner in Swedol AB (publ).The Board of Directors in Swedol AB (publ) has been informed of the offer. Swedol AB (publ) does not participate in the offer and will not be charged with any costs that are attributable to the offer. Tomas Billing                                        CEO                                                     Nordstjernan AB

SRV renovates premises for the Lahti University of Applied Sciences

SRV GROUP PLC                         PRESS RELEASE                            20 FEBRUARY  2017, AT 10.00SRV renovates premises for the Lahti University of Applied Sciences SRV has been selected to renovate premises for the Lahti University of Applied Sciences (LAMK) in Isku’s old industrial property at Mukkulankatu. The renovation is already underway, and LAMK will move to the new premises in autumn 2018.  “The new campus of LAMK is a good example of how an old, historical industrial property can find new life through adaptive renovation for a new use. We will implement a new,

Looking for the perfect match?

(UPM, Helsinki, 20 February 2017 at 10:00 EET) - You don't have to wonder anymore, whether and where you can find a suitable paper for your digital printing machine. UPM introduces the DIGI Matchmaker - an online tool developed to assist in finding the paper perfectly matching your requirements from our UPM Digi papers range. Using the DIGI Matchmaker is simple: Once you have chosen the digital printing method of your choice and defined the digital printing machine you are using, the DIGI Matchmaker introduces the perfectly matching results from UPM Digi paper offering. UPM is

Contactless VISA mobile payments powered by MeaWallet

MeaWallet technology has enabled customers of the Serbian bank Komercijalna banka, also called Kombank, to perform contactless transactions at POS terminals. The bank launched this new feature on the 2nd February, 2017 to their mobile banking application, KOMePay.Kombank is the largest state owned bank in Serbia. They have a strong and active strategy with a key focus on digital banking. In an interview published in November 2016 on b92.net, “Digital banking era has arrived”, the CEO of Kombank, Alexander Picker stated the following: Digital banking is the next stage in the development

Redeye: Initiates analyst coverage of Imint Image Intelligence

With the announcement of a number of license deals, Imint has shown that its Vidhance software is now a commercial product. We therefore feel confident that Imint is on the verge of its commercial breakthrough. Our fair values range between 22 and 135 SEK. Read more and download the analysis by Johan Ekström: https://goo.gl/jkRPS2 Become a member at Redeye in order access the latest analyses and updates. This is a press release from Redeye - Research Powered Investment Banking. http://beta.redeye.se/

Autoliv declares increased dividend

(Stockholm, Sweden, February 20, 2017) – – – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, today announced that its Board of Directors has declared a quarterly dividend of 60 cents per share for the second quarter 2017, an increase of 2 cents per share from the previous level.The dividend will be payable on Thursday, June 1, 2017 to Autoliv shareholders of record on the close of business on Wednesday, May 17. The ex-date will be Monday, May 15 for holders of the common stock listed on the New York Stock Exchange and Tuesday, May 16 for

Brighter signs agreement with Sonat for global logistics solution.

Brighter has selected Sonat as its development partner for the upcoming launch of Actiste®, Brighter’s connected diabetes solution. Sonat specializes in developing, managing and running logistics processes, and will together with Brighter develop a strong logistics platform that facilitates growth and international expansion. Under the agreement, Sonat will take on a partner role and drive the development of a logistics platform that enables rapid growth and expansion to new markets. Sonat will also act as an outsourced logistics function, which includes responsibility for forecasts,

Opus Group to start vehicle inspection program in Córdoba, Argentina on March 1, 2017

Opus will acquire three vehicle inspection concessions in Córdoba, Argentina, under an asset purchase agreement with Inspecentro, a Portuguese vehicle inspection company.  A purchase price is not disclosed at this time due to competitive reasons. The transaction is expected to be closed by end of February 2017.The government of Córdoba assigned its three concessions for vehicle inspection in Córdoba to Opus’ Argentinian subsidiary, Opus Inspection SA. Starting March 1, 2017, Opus will perform vehicle inspection mandated for all vehicles registered in Córdoba. The concessions include the

Sivers IMA enters partnership with Integrated Device Technology

Today Sivers IMA announces a partnership with Integrated Device Technology, Inc. (NASDAQ: IDTI) to provide a state-of-the-art mmWave V-band solution for infrastructure applications. The joint solution will be based on the IEEE 802.11ad standard and incorporate the new IDT® RapidWave ™ dual modem together with the new Sivers IMA high-end RFIC TRX-BF01.This new 60 GHz RFIC contains a beam forming transceiver including 16 Tx and 16 Rx channels. Sivers IMA will

Recipharm completes strategic acquisition in India

Recipharm AB (publ) (“Recipharm” or the “Company”) announces today that it has now concluded the acquisition of Kemwell’s pharmaceutical businesses located in Bengaluru, India.Highlights · Expands position in emerging markets significantly, taking sales in these markets to more than SEK 800 million [1], dominated by sales directly to the fast-growing pharma market in India. · Major extension of Recipharm’s capabilities in India: · Provides access to significantly increased development operation both in scale and breadth of capabilities. · Already working with customers

Evolution signs agreement with White Hat Gaming for Live Casino provision

Evolution Gaming, leading provider of Live Casino solutions, has announced that it has signed an agreement with gaming platform provider White Hat Gaming.Under the agreement White Hat Gaming will extend its existing casino content offering with Evolution’s award-winning Live Casino games portfolio for desktop, tablet and smartphone. The move gives White Hat Gaming access to the full range of Evolution mainstream and VIP Live Casino games including Live Roulette, Baccarat and Blackjack, plus numerous poker variants including exclusive titles, and a new Progressive Jackpot. The Evolution

Year-end Report 2016

Fourth quarter 2016 compared to 2015, Group » Group net sales increased by 168% to SEK 1,007,759 (375,368). » Other operating income amounted to SEK 821,447 (1,849,848) and is related to capitalized development costs. » Loss for the period amounted to SEK -18,454,211 (-14,148,843). » Earnings per share (weighted average) amounted to SEK -1,16 (-0.89). Twelve months 2016, compared to 2015, Group »    Group net sales increased by 137% to SEK 2,405,614 (1,016,462). »    Other operating income amounted to SEK 1,859,976 (5,628,598) and is related to capitalized development

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2016

Biohit Oyj Financial Statement Release, 20 February 2017 at 9:30 am local time (EET) SUMMARY January–December 2016 · Net sales grew by 35.4% compared to 1-12/2015 · Net sales EUR 8.2 million (EUR 6.1 million) · Operating loss, EUR -3.4  million (EUR -2.9 million) · The result for the reporting period was EUR -3.3  million (EUR -2.9 million) · Net sales from international operations 92.2% (88.3%) of total net sales · Equity ratio 83.0% (87.9%) July-December 2016 · Net sales grew by 72.8% compared to 7-12/2015 · Net sales EUR 4.4  million (EUR 2.5 million)

Biohit Oyj’s CEO Semi Korpela will return to work on 20.2.2017

Biohit Oyj Stock Exchange Release February 20, 2017 9:29 am local time (EEST) Biohit Oyj announced on January 5, 2017 that CEO Semi Korpela would take a sick leave of approximately one month, related to pneumonia and recovery from it. Korpela has recovered from his illness and will return to work on 20.2.2017. “I am full of energy”, says CEO Semi Korpela. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fiwww.biohithealthcare.com   Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology

Orkla ASA: Orkla initiates share buyback program

Orkla ASA (''Orkla'') has decided to initiate a share buyback program for up to 1.5 million shares in the market. The buyback program will be conducted in accordance with the authorization provided by the annual general meeting to the board of directors on 14 April 2016. The buyback will be executed according to the market price on the Oslo Stock Exchange. The program will be initiated today and terminated on 12 April 2017 at the latest. The shares purchased under this program will be used for Orkla's stock- and incentive program for own employees.Orkla ASAOslo, 20 February 2017

Hope for new treatment for Huntington’s disease

Researchers working at Karolinska Institutet in Sweden and University of Southern Denmark have managed to produce short synthetic DNA analogues – oligonucleotides – that bind direct to the gene that is mutated in Huntington’s disease and prevent the production of a protein that damages the nerve cells. The discovery, published in the journal Nucleic Acids Research, opens the way for new approaches to treating the currently untreatable and deadly neurodegenerative disease.Huntington’s disease is a devastating inherited condition that produces a combination of neurological, motor, cognitive

AZ licenses Zoladex to TerSera for the US & Canada

This announcement contains inside information 20 February 2017 07:00GMT ASTRAZENECA ENTERS AGREEMENT WITH TERSERA THERAPEUTICS FOR ZOLADEX IN THE US AND CANADA AstraZeneca to receive upfront payment and sustainable and ongoing sales-based income Agreement expands the commercial potential of Zoladex in US and Canada AstraZeneca today announced that it has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist,

The Nomination Committee´s proposal to Swedbank´s Annual General Meeting 2017

The Nomination Committee of Swedbank proposes election of Mats Granryd, Bo Johansson, Annika Poutiainen and Magnus Uggla as new members. Furthermore, the Nomination Committee proposes re-election of the present board members Lars Idermark, Ulrika Francke, Siv Svensson, Bodil Eriksson and Peter Norman. Göran Hedman, Pia Rudengren and Karl-Henrik Sundström have declined re-election. The proposition entails an increase of the number of the Board members elected by the Annual General Meeting from eight to nine. Lars Idermark is proposed as Chair of the Board of Directors.The Nomination

Orexo Completes Bond Buyback Program

Uppsala, Sweden – February 20, 2017 – Orexo AB (publ.) announces that it has successfully completed a limited bond buyback program and in total purchased Orexo corporate bonds in the market with a nominal value of MSEK 59. The program was initiated on February 8, 2017, and completed by February 17, 2017. After the purchase Orexo owns own bonds with a nominal value of MSEK 158. Pareto Securities and Danske Bank assisted Orexo in this process. For more information please contact: Orexo AB (publ.)Henrik Juuel, EVP and CFO Lena Wange, IR & Communications ManagerTel: +46 (0)18 780

Summa Equity acquires Lin Education

20 February 2017 Summa Equity has acquired Linfre Education AB from the founder and a handful of private investors. The founder and CEO Josef Lind will reinvest the majority of his proceeds, and the management team will also invest alongside Summa Equity.Tommi Unkuri, Partner at Summa Equity, said: “We are very excited about concluding Summa Equity’ third investment, and the first one within the investment theme Changing Demographics. This investment also fits within another of our four themes, Tech-enabled business, where Education is a core segment. Through Lin Education we will

ISOFOL FILES IMPORTANT NEW US PATENT APPLICATION

Isofol Medical AB (publ) today announces that a new patent application was filed, on February 14, 2017, to the US Patent and Trademark Office. As basis for the application Isofol has inserted new findings in relation to the clinical effect of Modufolin® as well as other research data. Using a universally accepted biomarker for the activity of the enzyme thymidylate synthase (TS), Isofol has completed a first comparison of the effects of Isofol’s Modufolin® compared with today’s standard folate, leucovorin (LV) in patients with colorectal cancer. Modufolin®-administration, as an example,

Ericsson partners with iQIYI and China Unicom to improve iQiYi video app experience

·         iQIYI, China's biggest video streaming app, has teamed up with Ericsson and China Unicom to optimize mobile network conditions and offer better viewing experience for its users.  ·         Ericsson App Experience Optimization Solution will increase on-app time and user engagement for iQIYI app via China Unicom's 3G and 4G networks Ericsson (NASDAQ: ERIC) announced today that it has been collaborating with China's leading video streaming service provider iQIYI and major telecommunication operator China Unicom to provide better app experiences for iQIYI' s users. Founded in

There are no items matching the current filter
There are no more items matching the current filter
Back to top